Table 1.

Evaluation of 6 different immunologic parameters in patients treated with anti-CTLA-4

Patients with bladder cancer who received anti-CTLA-4 therapy
% ICOS+ CD4 T-cells
Patient	Pre-treatment	Post-treatment (dose #1)	Post-treatment (dose #2)
1	1.4	13.5	8.7
2	1.9	9.7	21.7
3	2.8	9.7	40.1
4	1.9	14.2	6.4
5	4.2	16.6	27.8
6	2.9	13.5	6.6

% HLA-DR+ CD4 T-cells
Patient	Pre-treatment	Post-treatment (dose #1)	Post-treatment (dose #2)
1	3.5	6.5	3.4
2	1.2	3.0	1.2
3	1.9	8.3	5.2

% CD25+ CD4 T-cells
Patient	Pre-treatment	Post-treatment (dose #1)	Post-treatment (dose #2)
1	6.8	10.9	18.8
2	30.7	31.3	38.5
3	43.0	37.4	38.5

% CD4 T-cells
Patient	Pre-treatment	Post-treatment (dose #1)	Post-treatment (dose #2)
1	52.7	51.3	51.5
2	32.1	40.5	43.5
3	41.0	37.1	23.7
4	46.9	45.0	45.4
5	22.4	41.7	35.3
6	29.6	35.7	34.3

% CD8 T-cells
Patient	Pre-treatment	Post-treatment (dose #1)	Post-treatment (dose #2)
1	11.5	6.7	10.8
2	12.0	15.3	22.7
3	11.5	10.5	5.8
4	16.1	13.2	26.0
5	6.1	6.8	5.8
6	9.3	8.9	7.5

Absolute lymphocyte count (k/ul)
Patient	Pre-treatment	Post-treatment (dose #1)	Post-treatment (dose #2)
1	2.34	3.17	1.86
2	3.51	4.63	5.13
3	1.88	1.91	0.95
4	3.94	2.82	4.49
5	0.76	1.13	1.08
6	0.90	2.83	3.21